will come iStock | Getty Images
modern and Merck’s experimental cancer vaccine, used in conjunction with Markof Keytruda, reduced the risk of the most severe form skin cancer In a clinical trial, spread to other parts of the body, according to the intermediate stage trial Results published on Monday.
Moderna and Marx’s cancer vaccines reduce risk Melanoma Spread to other parts of the body or stage 3 or 4 death in 65% of patients disease Compared with patients receiving only Merck’s immunotherapy treatment, the trial found.
Moderna and Merck will present the data at the American Society of Clinical Oncology’s annual conference in Chicago at 5 pm ET.
The clinical trial enrolled 157 patients who had their cancer surgically removed.
Patients in the treatment group received a total of nine doses every three weeks and a 200 mg Keytruda intravenous infusion every three weeks for a total of 1 mg injection every three weeks for approximately one year.
According to the American Cancer Society, melanoma is the leading cause of skin cancer deaths. According to the society, melanoma rates have increased rapidly over the past few decades.
About 100,000 people in the U.S. are expected to be diagnosed with melanoma this year, and about 8,000 people are expected to die from the disease, according to the society.
Data released Monday are the latest promising results from Moderna and Merck.
The companies released data in April showing that the combination of Moderna and Merck’s cancer vaccine Keytruda reduced the risk of melanoma recurrence by 44% compared with those who received Merck’s immunotherapy treatment alone.
The Food and Drug Administration granted Moderna and Merck a breakthrough therapy designation in February, intended to accelerate the development and review of treatments for serious and life-threatening diseases.
Correction: This story has been updated to reflect that the vaccine is jointly developed by Moderna and Merck.
Where we collect the information from Source link
Disclaimer:- We include in each post a link to where each content on our website is collected from.If there is a complaint against any post please contact us directly.
Email: post-support.dailyfastnews24.com
You can also write on the popular online news portal dailyfastnews24.com. Writing topics feature, travel, lifestyle, career, IT, agriculture and nature. Send your entry today to [email protected]
advertisement:-If you would like to advertise on our website please contact us here.Our Ads team will contact you very soon.
Email: [email protected]
The cost of advertising:- 1 Post 100 USD Lifetime.
Thank you very much for visiting our website. Have a good day.